2014全球生物技术报告－安永会计事务所

秋云飞

6 Perspectives
7 Point of view
Unlocking value
10 Recognizing the value of personalized medicine
Mara G. Aspinall, Ventana Medical Systems Inc.
13 Capital efficiency in R&D: when more is more
Graziano Seghezzi, Sofinnova Partners
15 Navigating precision medicine requires going global and local
Kristin Pothier, EY, US
17 I-SPY more innovative trials
Peter Payne, eXcelerate Research Inc. and Dr. Meredith Buxton, I-SPY TRIALS Consortium
18 Solution development: a new approach to R&D
Dr. Peter Kolchinsky, RA Capital
20 Using adaptive design to change an asset’s risk profile
Dr. Nitin Patel, Cytel Inc.
23 Accelerating clinical development
Dr. Annalisa Jenkins, TransCelerate BioPharma
26 Big data in drug R&D
Chris Moore, EY, UK
27 Think like a payer
Dr. Silvia Ondategui-Parra, EY, Spain
30 New expedited regulatory pathways speed products to market
Rachel King, GlycoMimetics
32 Improving biopharma innovation: collaboration required
Dr. Elias Zerhouni, Sanofi
34 Preserving a culture of innovation
Dr. George Scangos, Biogen Idec
36 Financial performance
Commercial leaders
37 The big picture
40 United States
46 Europe
50 Canada
51 Australia
52 Financing
A biotech bounce
53 The big picture
58 United States
66 Canada
68 Europe
72 Deals
Biotech buyers
73 The big picture
80 Celgene: 2013’s top deal maker
81 United States
84 Europe
86 Products and pipeline
Seeking novelty
87 The big picture
90 United States
92 Europe
99 Acknowledgments
100 Data exhibit index
102 Global biotechnology contacts
Contents